SENL103

SENL103 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting the B-cell maturation antigen (BCMA), also known as TNFRSF17. It is being developed for the treatment of refractory generalized myasthenia gravis (gMG). The therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes BCMA, which is highly expressed on the surface of long-lived plasma cells. These plasma cells are responsible for the production of pathogenic autoantibodies (such as anti-AChR, anti-MuSK, or anti-LRP4) that disrupt neuromuscular transmission. By selectively depleting these plasma cells, SENL103 aims to reduce autoantibody titers and provide clinical benefit to patients who have not responded to conventional immunosuppressive treatments.

Other names

BCMA CAR-T (S103)SENL103 Autologous T-cell InjectionSENL-103 Autologous T-cell InjectionSENL 103 Autologous T-cell Injection